Health Robotics reported today that it conducted a retrospective review of records for all "live" patient doses at its global Oncology Robot customers as of December 4, 2012, right after Intelligent Hospital Systems announced that their RIVA medical device had produced that same day its "first-ever chemotherapy patient dose".
Elderly or people with osteoporosis, smokers, diabetics or people who have had cancer are sometimes not eligible to receive dental implants as their bones are unable to correctly integrate the new prostheses which replace the root. Researchers at the Universitat Jaume I (UJI) in Castellón have developed an implant coating with a novel biodegradable material aimed at people with bone deficit. It will also increase the overall success rate of implants through an enhanced biocompatibility and reduce the time of osseointegration or bone integration.
THE DOCTORS, an Emmy Award winning, nationally syndicated talk show, discussed hospital cleanliness and a unique disinfection solution, TRU-D SmartUVC™ offered by Philips Healthcare.
Reha Technology AG announced today the closing of financing by HBM BioCapital II LP; a private equity partnership advised by HBM Partners AG, Switzerland.
With the rapidly expanding use of brain and spinal cord stimulation therapy (neuromodulation), new "remote presence" technologies may help to meet the demand for experts to perform stimulator programming, reports a study in the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Hansen Medical, Inc., a global leader in intravascular robotics, today announced it will exhibit its Magellan™ Robotic System at the 25th Annual International Symposium on Endovascular Therapy (ISET), from January 19-23 at the Fontainebleau Miami Beach Hotel in Miami, FL. The Company will be exhibiting the Magellan Robotic System at Booth 509.
The Detroit Medical Center (DMC) announced today that a team of heart specialists at its Cardiovascular Institute (CVI) has successfully conducted the Midwest's first-ever "robotic-assisted" coronary revascularization to relieve heart artery blockages. The successful implementation of the pioneering new treatment procedure – unique in Michigan and so far performed at only three institutions in the United States – means that DMC heart care patients now have access to the world's most advanced treatment method for relieving blockages in heart arteries, said CVI President Theodore L. Schreiber , M.D.
Approximately one in every 1,000 people in the UK is an amputee. Many lose their limbs as the result of tragic accidents or due to active military combat and for some amputees losing a limb can feel like losing their freedom.
MAKO Surgical Corp., a medical device company that markets its RIO® Robotic Arm Interactive Orthopedic surgical platform, MAKOplasty® joint specific applications, and proprietary RESTORIS® implants that together enable orthopedic surgeons to consistently, reproducibly and precisely treat patient specific osteoarthritic disease, today announced its selected operating results for the fourth quarter and the year ended December 31, 2012 in anticipation of its business update presentation at the 31st Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 9, 2013 at 7:30 am PT.
It may look like a futuristic gadget from a science fiction movie, but this germ-killing robot is a new, efficient method of tackling hospital superbugs. As reported in the Daily Mail, the device kills hospital superbugs faster than before, and could save the NHS $325 million a year if adopted nationwide.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.